{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:29:34Z","timestamp":1761964174169,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.jneuroim.2008.04.001","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T04:32:27Z","timestamp":1210739547000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Distinct evolution of calcium channel antibody types in Lambert\u2013Eaton myasthenic syndrome"],"prefix":"10.1016","volume":"197","author":[{"given":"Nicole","family":"Martin-Moutot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"De Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Seagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2008.04.001_bib1","first-page":"513","article-title":"[Lambert\u2013Eaton syndrome: clinical and electrophysiological study of 18 cases associated with lung cancer]","volume":"148","author":"Bady","year":"1992","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000116917","article-title":"Lambert\u2013Eaton myasthenic syndrome and polyneuropathy in a patient with epidermoid carcinoma of the lung","volume":"33","author":"Comola","year":"1993","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/jphysiol.2002.021048","article-title":"Passive transfer of Lambert\u2013Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission","volume":"543","author":"Flink","year":"2002","journal-title":"J. Physiol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1023\/B:JOBB.0000008033.02320.10","article-title":"Ca2+ channels as targets of neurological disease: Lambert\u2013Eaton Syndrome and other Ca2+ channelopathies","volume":"35","author":"Flink","year":"2003","journal-title":"J. Bioenerg. Biomembranes"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bjp.0704818","article-title":"Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions","volume":"136","author":"Giovannini","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2008.04.001_bib7","doi-asserted-by":"crossref","first-page":"I14","DOI":"10.1007\/s00415-005-1104-5","article-title":"IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status","volume":"252","author":"Illa","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.pas.0000213319.04919.97","article-title":"Nonsmall cell lung carcinoma with neuroendocrine differentiation \u2014 an entity of no clinical or prognostic significance","volume":"31","author":"Ionescu","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1568-9972(02)00146-5","article-title":"Autoantibodies to ion channels at the neuromuscular junction","volume":"2","author":"Lang","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0025-6196(12)65705-X","article-title":"Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert\u2013Eaton myasthenic syndrome","volume":"64","author":"Lennon","year":"1989","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410290313","article-title":"Calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"29","author":"Leys","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert\u2013Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-5793(95)00467-N","article-title":"Properties of omega conotoxin MVIIC receptors associated with alpha 1A calcium channel subunits in rat brain","volume":"366","author":"Martin-Moutot","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib14","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0035-3787(04)71002-4","article-title":"[Dosage and specificity of anti-calcium channel antibodies in Lambert\u2013Eaton myasthenic syndrome]","volume":"160","author":"Martin-Moutot","year":"2004","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nbd.2005.10.003","article-title":"Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert\u2013Eaton myasthenic syndrome","volume":"22","author":"Martin-Moutot","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s004150050303","article-title":"Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert\u2013Eaton myasthenic syndrome","volume":"246","author":"Nakao","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert\u2013Eaton myasthenic syndrome: study of 110 Japanese patients","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib19","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","article-title":"Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert\u2013Eaton myasthenic syndrome","volume":"20","author":"Oh","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert\u2013Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib21","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.95.14.8328","article-title":"Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons","volume":"95","author":"Pinto","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.46.5.1391","article-title":"Calcium channel blockers and transmitter release at the normal human neuromuscular junction","volume":"46","author":"Protti","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","article-title":"Lambert\u2013Eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0306-4522(99)00382-6","article-title":"Multiple types of calcium channels mediate transmitter release during functional recovery of botulinum toxin type A-poisoned mouse motor nerve terminals","volume":"95","author":"Santafe","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(89)90893-3","article-title":"Specificity of calcium channel autoantibodies in Lambert\u2013Eaton myasthenic syndrome","volume":"2","author":"Sher","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-510X(95)00162-U","article-title":"Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert\u2013Eaton myasthenic syndrome","volume":"133","author":"Takamori","year":"1995","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0761-8425(04)71594-6","article-title":"[Difficulties associated with Lambert\u2013Eaton syndrome]","volume":"21","author":"Tchouhadjian","year":"2004","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib28","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","article-title":"Lambert\u2013Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment","volume":"54","author":"Tim","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib29","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1073\/pnas.0437991100","article-title":"Altered properties of quantal neurotransmitter release at endplates of mice lacking P\/Q-type Ca2+ channels","volume":"100","author":"Urbano","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2008.04.001_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5","article-title":"P\/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system","volume":"22","author":"Voltz","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.04.001_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert\u2013Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz","year":"2005","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557280800091X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557280800091X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:08:32Z","timestamp":1759046912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557280800091X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S016557280800091X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.04.001","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct evolution of calcium channel antibody types in Lambert\u2013Eaton myasthenic syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}